A. V. Melnik, V. E. Solovyova, Yu. O. Yatsenko, A. E. Filippova, E. G. Asryan, T. Е. Seitumerov, E. R. Myshak, Yu. A. Chernysheva, S. A. Ziyadinova, V. O. Kononenko, M. R. Kadyrova, A. A. Denisenko, K. T. Ismagilova, D. V. Mushinsky, L. Sorokina
{"title":"用于子痫前期预测和早期诊断的转录组图谱评估","authors":"A. V. Melnik, V. E. Solovyova, Yu. O. Yatsenko, A. E. Filippova, E. G. Asryan, T. Е. Seitumerov, E. R. Myshak, Yu. A. Chernysheva, S. A. Ziyadinova, V. O. Kononenko, M. R. Kadyrova, A. A. Denisenko, K. T. Ismagilova, D. V. Mushinsky, L. Sorokina","doi":"10.17749/2313-7347/ob.gyn.rep.2024.521","DOIUrl":null,"url":null,"abstract":"Aim: to develop a model for predicting preeclampsia (PE) based on the clinically most significant differentially expressed plasma microRNAs.Materials and Methods. A prospective observational comparative study was conducted with 62 women, divided into two parallel groups: 32 patients with PE and 30 clinically healthy women with uncomplicated pregnancy. Transcriptomic analysis was performed to identify differentially expressed blood plasma microRNAs using next generation sequencing (NGS).Results. Calculation of risk ratios for PE development allowed to identify 14 plasma microRNAs that influence the development of PE pathology. PE-associated microRNAs hsa-miR-103a-3p, hsa-miR-451a and hsa-miR-516a-5p have a high diagnostic value when combined to assess their blood plasma expression level in early pregnancy stages.Conclusion. The developed prognostic model can be applied to pregnant women at risk for PE development, which may further reduce obstetric complications and improve perinatal outcomes.","PeriodicalId":36521,"journal":{"name":"Obstetrics, Gynecology and Reproduction","volume":"113 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transcriptomic profile assessment for preeclampsia prediction and early diagnostics\",\"authors\":\"A. V. Melnik, V. E. Solovyova, Yu. O. Yatsenko, A. E. Filippova, E. G. Asryan, T. Е. Seitumerov, E. R. Myshak, Yu. A. Chernysheva, S. A. Ziyadinova, V. O. Kononenko, M. R. Kadyrova, A. A. Denisenko, K. T. Ismagilova, D. V. Mushinsky, L. Sorokina\",\"doi\":\"10.17749/2313-7347/ob.gyn.rep.2024.521\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: to develop a model for predicting preeclampsia (PE) based on the clinically most significant differentially expressed plasma microRNAs.Materials and Methods. A prospective observational comparative study was conducted with 62 women, divided into two parallel groups: 32 patients with PE and 30 clinically healthy women with uncomplicated pregnancy. Transcriptomic analysis was performed to identify differentially expressed blood plasma microRNAs using next generation sequencing (NGS).Results. Calculation of risk ratios for PE development allowed to identify 14 plasma microRNAs that influence the development of PE pathology. PE-associated microRNAs hsa-miR-103a-3p, hsa-miR-451a and hsa-miR-516a-5p have a high diagnostic value when combined to assess their blood plasma expression level in early pregnancy stages.Conclusion. The developed prognostic model can be applied to pregnant women at risk for PE development, which may further reduce obstetric complications and improve perinatal outcomes.\",\"PeriodicalId\":36521,\"journal\":{\"name\":\"Obstetrics, Gynecology and Reproduction\",\"volume\":\"113 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrics, Gynecology and Reproduction\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.521\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics, Gynecology and Reproduction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.521","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的:根据血浆中具有临床意义的差异表达的微RNA,建立预测子痫前期(PE)的模型。研究人员对 62 名妇女进行了前瞻性观察比较研究,将其分为两组:32 名子痫前期患者和 30 名临床健康的无并发症妊娠妇女。利用新一代测序技术(NGS)进行转录组分析,以确定血浆中表达不同的 microRNA。通过计算PE发生的风险比,确定了14种影响PE病理发展的血浆microRNA。与 PE 相关的 microRNA hsa-miR-103a-3p、hsa-miR-451a 和 hsa-miR-516a-5p 在妊娠早期的血浆表达水平评估中具有较高的诊断价值。所开发的预后模型可应用于有发生 PE 风险的孕妇,从而进一步减少产科并发症,改善围产儿预后。
Transcriptomic profile assessment for preeclampsia prediction and early diagnostics
Aim: to develop a model for predicting preeclampsia (PE) based on the clinically most significant differentially expressed plasma microRNAs.Materials and Methods. A prospective observational comparative study was conducted with 62 women, divided into two parallel groups: 32 patients with PE and 30 clinically healthy women with uncomplicated pregnancy. Transcriptomic analysis was performed to identify differentially expressed blood plasma microRNAs using next generation sequencing (NGS).Results. Calculation of risk ratios for PE development allowed to identify 14 plasma microRNAs that influence the development of PE pathology. PE-associated microRNAs hsa-miR-103a-3p, hsa-miR-451a and hsa-miR-516a-5p have a high diagnostic value when combined to assess their blood plasma expression level in early pregnancy stages.Conclusion. The developed prognostic model can be applied to pregnant women at risk for PE development, which may further reduce obstetric complications and improve perinatal outcomes.